65 related articles for article (PubMed ID: 8855388)
1. Tuning between Nuclear Organization and Functionality in Health and Disease.
Manda NK; Golla U; Sesham K; Desai P; Joshi S; Patel S; Nalla S; Kondam S; Singh L; Dewansh D; Manda H; Rokana N
Cells; 2023 Feb; 12(5):. PubMed ID: 36899842
[TBL] [Abstract][Full Text] [Related]
2. The diagnostic and prognostic value of nuclear matrix protein 22 in bladder cancer.
Tang X; Cao Y; Liu J; Wang S; Yang Y; Du P
Transl Cancer Res; 2020 Nov; 9(11):7174-7182. PubMed ID: 35117321
[TBL] [Abstract][Full Text] [Related]
3. Plasma DNA Integrity as a Prognostic Biomarker for Colorectal Cancer Chemotherapy.
Zhu F; Ma J; Ru D; Wu N; Zhang Y; Li H; Liu X; Li J; Zhang H; Xu Y; Zhao J; Tang H; Wang Y; Fu W
J Oncol; 2021; 2021():5569783. PubMed ID: 34135960
[TBL] [Abstract][Full Text] [Related]
4. Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients.
Siravegna G; Bardelli A
Mol Oncol; 2016 Mar; 10(3):475-80. PubMed ID: 26774880
[TBL] [Abstract][Full Text] [Related]
5. What are the currently available and in development molecular markers for bladder cancer? Will they prove to be useful in the future?
Abdulmajed MI; Sancak EB; Reşorlu B; Al-Chalaby GZ
Turk J Urol; 2014 Dec; 40(4):228-32. PubMed ID: 26328183
[TBL] [Abstract][Full Text] [Related]
6. Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer.
Hao TB; Shi W; Shen XJ; Qi J; Wu XH; Wu Y; Tang YY; Ju SQ
Br J Cancer; 2014 Oct; 111(8):1482-9. PubMed ID: 25157833
[TBL] [Abstract][Full Text] [Related]
7. Nucleophosmin1 associated with drug resistance and recurrence of bladder cancer.
Hu H; Meng Q; Lei T; Zhang M
Clin Exp Med; 2015 Aug; 15(3):361-9. PubMed ID: 24925635
[TBL] [Abstract][Full Text] [Related]
8. Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder.
Santoni M; Catanzariti F; Minardi D; Burattini L; Nabissi M; Muzzonigro G; Cascinu S; Santoni G
Adv Urol; 2012; 2012():397412. PubMed ID: 22811704
[TBL] [Abstract][Full Text] [Related]
9. In the cystoscopic follow-up of non-muscle-invasive transitional cell carcinoma, NMP-22 works for high grades, but unreliable in low grades and upper urinary tract tumors.
Coskuner E; Cevik I; Ozkan A; Dillioglugil O; Akdas A
Int Urol Nephrol; 2012 Jun; 44(3):793-8. PubMed ID: 22371126
[TBL] [Abstract][Full Text] [Related]
10. Urine cytology and adjunct markers for detection and surveillance of bladder cancer.
Sullivan PS; Chan JB; Levin MR; Rao J
Am J Transl Res; 2010 Jul; 2(4):412-40. PubMed ID: 20733951
[TBL] [Abstract][Full Text] [Related]
11. Defining the role of NMP22 in bladder cancer surveillance.
Nguyen CT; Jones JS
World J Urol; 2008 Feb; 26(1):51-8. PubMed ID: 18058108
[TBL] [Abstract][Full Text] [Related]
12. Alternatives to cytology in the management of non-muscle invasive bladder cancer.
Amiel GE; Shu T; Lerner SP
Curr Treat Options Oncol; 2004 Oct; 5(5):377-89. PubMed ID: 15341676
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of nuclear matrix protein 22 (NMP22) as a tumor marker in the detection of bladder cancer.
Oge O; Atsü N; Kendi S; Ozen H
Int Urol Nephrol; 2001; 32(3):367-70. PubMed ID: 11583354
[TBL] [Abstract][Full Text] [Related]
14. The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder.
Shelfo SW; Soloway MS
World J Urol; 1997; 15(2):107-11. PubMed ID: 9144900
[TBL] [Abstract][Full Text] [Related]
15. Utilization of nuclear matrix proteins for cancer diagnosis.
Keesee SK; Briggman JV; Thill G; Wu YJ
Crit Rev Eukaryot Gene Expr; 1996; 6(2-3):189-214. PubMed ID: 8855388
[TBL] [Abstract][Full Text] [Related]
16. Detection of nuclear matrix proteins in serum from cancer patients.
Miller TE; Beausang LA; Winchell LF; Lidgard GP
Cancer Res; 1992 Jan; 52(2):422-7. PubMed ID: 1728414
[TBL] [Abstract][Full Text] [Related]
17. Bladder cancer-associated nuclear matrix proteins.
Getzenberg RH; Konety BR; Oeler TA; Quigley MM; Hakam A; Becich MJ; Bahnson RR
Cancer Res; 1996 Apr; 56(7):1690-4. PubMed ID: 8603421
[TBL] [Abstract][Full Text] [Related]
18. The utilization of nuclear matrix proteins for cancer diagnosis.
Replogle-Schwab R; Pienta KJ; Getzenberg RH
Crit Rev Eukaryot Gene Expr; 1996; 6(2-3):103-13. PubMed ID: 8855384
[TBL] [Abstract][Full Text] [Related]
19. Nuclear mitotic apparatus protein (NuMA) in benign and malignant diseases.
Hasholzner U; Stieber P; Zimmermann A; Burges A; Hofmann K; Schmitt UM; Schmeller N; Schalhorn A
Anticancer Res; 1999; 19(4A):2415-20. PubMed ID: 10470168
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
